Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
Top Page
Shattuck Labs
(NASDAQ:STTK)
44Neutral
Positive Factors
Financial Position
The company remains well-financed with a cash runway expected to fund development into 2027.
Preclinical Data
No evidence of toxicity or organ damage was observed in preclinical trials of SL-325.
Negative Factors
Product Development Challenges
SL-325 is at least a year from the clinic (IND expected 3Q25) and thus is unlikely to drive share value in the near-term.
Shattuck Labs (STTK) vs. S&P 500 (SPY)
Market Cap
$62.06M
Dividend YieldN/A
Average Volume (3M)194.78K
Price to Earnings (P/E)―
Beta (1Y)2.71
Revenue Growth382.75%
EPS Growth31.68%
CountryUS
Employees75
SectorHealthcare
Sector Strength78
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.53
Shares Outstanding47,739,708
10 Day Avg. Volume168,714
30 Day Avg. Volume194,778
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)9.13
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Shattuck Labs Business Overview & Revenue Model
Company DescriptionShattuck Labs (STTK) is a biotechnology company focused on the development of novel therapeutics for the treatment of cancer and autoimmune diseases. The company leverages its proprietary Agonist Redirected Checkpoint (ARC) platform to create fusion proteins that modulate the immune system. These innovative therapies aim to enhance the body's natural immune response to fight diseases more effectively, providing a promising approach to addressing unmet medical needs in oncology and immunology.
How the Company Makes MoneyShattuck Labs generates revenue primarily through partnerships and collaborations with larger pharmaceutical companies. These collaborations often involve licensing agreements, milestone payments, and royalties related to the development and commercialization of their proprietary ARC platform-based therapies. Additionally, the company may receive funding from research grants and government programs aimed at supporting innovative biotech research. While Shattuck Labs is in the clinical development stage, a significant portion of its income is derived from these strategic partnerships and collaborations, which provide both upfront payments and potential royalties upon successful commercialization of its therapeutic candidates.
Shattuck Labs Financial Statement Overview
Summary
Shattuck Labs exhibits promising revenue growth but faces significant profitability and cash flow challenges. The balance sheet is strong with low leverage, but declining asset values raise concerns about future stability. Focus on operational efficiency and cash flow management is critical.Income Statement
Shattuck Labs has shown a significant increase in revenue from $1.66 million in 2023 to $6.43 million in TTM (Trailing-Twelve-Months), indicating strong revenue growth. However, the company continues to struggle with profitability, evidenced by negative gross profit margins and a substantial net loss of $74.42 million in TTM. The EBIT and EBITDA margins remain deeply negative, reflecting ongoing operational challenges.35
Negative
Balance Sheet
The company's balance sheet shows a strong equity position with $96.58 million in stockholders' equity and a low debt-to-equity ratio, thanks to minimal total debt of $3.61 million. However, the declining total assets and equity over time suggest potential risks in long-term financial stability. The equity ratio remains favorable, providing a buffer against liabilities.45
Neutral
Cash Flow
Operating cash flow remains negative at $62.56 million in TTM, though improved from previous periods, indicating ongoing cash burn. Free cash flow growth remains challenging due to substantial negative free cash flow. The operating cash flow to net income ratio is unfavorable, reflecting inefficient cash generation relative to net losses.40
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 6.43M | 1.66M | 652.00K | 30.02M | 9.93M | 9.89M | Gross Profit |
| -14.76M | -2.38M | -2.72M | 28.64M | -27.55M | -19.11M | EBIT |
| -79.88M | -91.96M | -103.33M | -45.27M | -36.93M | -25.07M | EBITDA |
| -75.71M | -87.61M | -100.26M | -43.89M | -36.31M | -24.53M | Net Income Common Stockholders |
| -74.42M | -87.30M | -100.56M | -44.35M | -35.44M | -23.88M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 60.38M | 130.63M | 161.28M | 268.80M | 335.45M | 39.09M | Total Assets |
| 0.00 | 159.56M | 205.32M | 298.58M | 348.99M | 44.97M | Total Debt |
| 0.00 | 4.20M | 4.20M | 0.00 | 0.00 | 0.00 | Net Debt |
| 60.38M | -121.42M | -43.18M | -92.27M | -157.90M | -7.01M | Total Liabilities |
| 0.00 | 14.86M | 29.17M | 26.80M | 39.13M | 79.52M | Stockholders Equity |
| 37.98M | 144.71M | 176.16M | 271.79M | 309.86M | -34.55M |
| Cash Flow | Free Cash Flow | ||||
| -62.64M | -81.64M | -106.11M | -65.04M | -34.39M | -21.45M | Operating Cash Flow |
| -62.56M | -81.23M | -94.50M | -57.12M | -33.66M | -20.98M | Investing Cash Flow |
| 16.34M | 110.86M | 49.44M | -10.44M | -146.32M | -3.59M | Financing Cash Flow |
| 49.42M | 48.62M | 171.00K | 1.93M | 330.87M | -64.00K |
Shattuck Labs Technical Analysis
Positive
1.23
Price Trends
1.25
Positive
1.23
Positive
2.67
Negative
Market Momentum
<0.01
Positive
50.41
Neutral
22.69
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For STTK, the sentiment is Positive. The current price of 1.23 is below the 20-day moving average (MA) of 1.33, below the 50-day MA of 1.25, and below the 200-day MA of 2.67, indicating a neutral trend. The MACD of <0.01 indicates Positive momentum. The RSI at 50.41 is Neutral, neither overbought nor oversold. The STOCH value of 22.69 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for STTK.
Shattuck Labs Risk Analysis
Shattuck Labs disclosed 55 risk factors in its most recent earnings report. Shattuck Labs reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Shattuck Labs Peers Comparison
Overall Rating
UnderperformOutperform
Sector (49)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
49 Neutral | $6.90B | -0.08 | -53.01% | 2.43% | 24.84% | -3.06% | |
45 Neutral | $676.11M | ― | -29.06% | ― | 30.27% | 44.12% | |
44 Neutral | $62.06M | ― | -71.09% | ― | 382.75% | 31.68% | |
44 Neutral | $114.38M | ― | -53.54% | ― | 145.37% | 57.01% | |
42 Neutral | $537.10M | ― | -17.48% | ― | ― | ― | |
38 Underperform | $47.70M | ― | -88.91% | ― | ― | 30.37% |
* Healthcare Sector Average
Performance Comparison
STTK
Shattuck Labs
1.30
-7.43
-85.11%
ADAP
Adaptimmune Therapeutics
0.45
-1.04
-69.80%
BCYC
Bicycle Therapeutics
10.20
-14.84
-59.27%
IMTX
Immatics
4.45
-7.55
-62.92%
ALXO
ALX Oncology Holdings
0.97
-11.40
-92.16%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.